Skip to content

Fulgent Genetics

US · FLGT #3667 by market cap Listed 2016
24.12 -0.66 -2.66%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

After-hours 24.12 0.00%
26.1516.5524.122026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on FLGT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +2.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 7.3% of float.
  • Analyst tilt is Hold.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth F

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) -19.5% Better than 2%
Free cash flow CAGR (3Y) -64.3% Better than 2%
Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 40.6% Better than 49%
Operating margin -28.2% Better than 11%
Net margin -18.8% Better than 13%
Return on equity -5.4% Better than 23%
Return on invested capital -7.8% Better than 19%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 21.2% Better than 97%
6-month return 41.0% Better than 93%
12-month return (ex latest month) -33.0% Better than 8%
Distance below 52-week high 22.3% Better than 56%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.5x Better than 90%
Debt to assets 0.6% Better than 95%
Interest coverage -932.7x Better than 2%
Free cash flow / net income 163.7% Better than 69%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.19%
1M +18.64%
3M +21.08%
6M +46.98%
YTD -8.18%
1Y -16.19%
3Y -12.67%
5Y -74.33%

Key statistics

Price & volume

Prev close
24.78
Open
24.50
Day range
23.88 - 24.79
Avg price
24.16
Volume
322.99K
Turnover
7.80M
Amplitude
3.67%
52-week range
13.46 - 31.04

Valuation

P/E
-12.24
P/E (TTM)
-7.78
P/B
0.68
EPS
-1.97
Net profit
-55.04M
Net assets
990.49M

Share structure

Market cap
673.89M
Float cap
413.02M
Shares out
27.94M
Float shares
17.12M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-09-29
52-week range 61% of range
13.46 31.04

22.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.78M net over the window

Short interest

Shares short
2.02M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Fulgent Genetics (FLGT)?

Fulgent Genetics last traded at 24.12. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Fulgent Genetics's market cap?

About 673.89M.

What is the P/E ratio of Fulgent Genetics?

The trailing twelve-month P/E is -7.78. The Valuation tab shows it against the stock's own five-year range.

Does Fulgent Genetics pay a dividend?

Fulgent Genetics does not currently pay a regular dividend.

Is Fulgent Genetics a buy according to analysts?

The consensus of 1 analysts is a Hold rating, with an average 12-month price target of 19.00, which implies 21.2% downside from the current price. This is not investment advice.

What is Fulgent Genetics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Fulgent Genetics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Fulgent Genetics discussion 0 comments

Add a comment